2005•Sichuan Journal of Cancer ControlRequires access
The Clinical Study of the Regimen of CHOP Plus Rituximab in the Treatment of Refractory Non-Hodgkin′s Lymphoma
Wan You-feng
Open publisher page 0 citations
Abstract
Objective: To evaluate the efficacy of the regimen of CHOP Plus Rituximab in the treatment of refractory Non-Hodgkin′s lymphoma.Methods: 21 patients with Non-Hodgkin′s lymphoma were divided into two groups:treatment group(n=9) and control group(n=12).The patients in treatment group were treated with the regimen of CHOP and Rituximab,and the patients in control group were treated with the regimen of CHOP and etoposide and blemycin.Results: In the treatment group, the overall remission rate was 88.9%(10/11),the mean remission time was 14.9±2.7 months;and in the control group, the overall remission rate was 58.3%(7/12),the mean remission time was 3.6±2.1 months.The difference of the efficacy in the two groups is significant(P0.05).Conclusion: In the treatment of refactory NHL, the regimen of CHOP combined with Rituximab is more effective than other high dose chemotherapy.[